MYELODYSPLASTIC SYNDROME (MDS)
Clinical trials for MYELODYSPLASTIC SYNDROME (MDS) explained in plain language.
Never miss a new study
Get alerted when new MYELODYSPLASTIC SYNDROME (MDS) trials appear
Sign up with your email to follow new studies for MYELODYSPLASTIC SYNDROME (MDS), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Experimental drug ADCT-301 tested in just 3 patients – study halted early
Disease control TerminatedThis study tested a drug called ADCT-301 in people whose blood cancer (AML, MDS, or related conditions) came back after a stem cell transplant. Only 3 people took part before the study was stopped early. The goal was to see if the drug is safe and can help achieve remission. Risk…
Matched conditions: MYELODYSPLASTIC SYNDROME (MDS)
Phase: PHASE2 • Sponsor: Gwynn Long, M.D. • Aim: Disease control
Last updated May 26, 2026 03:16 UTC
-
New combo therapy for MDS shows promise in early trial
Disease control TerminatedThis study tested a new drug called sabatolimab added to standard chemotherapy for people with intermediate to very high risk myelodysplastic syndrome (MDS), a type of blood cancer. The main goal was to check safety and side effects. A total of 39 adults took part, but the study …
Matched conditions: MYELODYSPLASTIC SYNDROME (MDS)
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 26, 2026 03:14 UTC
-
New combo therapy shows promise for tough blood cancer
Disease control TerminatedThis study tested a new drug called sabatolimab combined with two standard treatments (azacitidine and venetoclax) in 20 adults with high-risk myelodysplastic syndromes (MDS) who could not have intensive chemotherapy or a stem cell transplant. The goal was to see if the combinati…
Matched conditions: MYELODYSPLASTIC SYNDROME (MDS)
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 26, 2026 03:11 UTC